Your browser doesn't support javascript.
loading
Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients.
Lee, Ian Y; Hanft, Simon; Schulder, Michael; Judy, Kevin D; Wong, Eric T; Elder, J Bradley; Evans, Linton T; Zuccarello, Mario; Wu, Julian; Aulakh, Sonikpreet; Agarwal, Vijay; Ramakrishna, Rohan; Gill, Brian J; Quiñones-Hinojosa, Alfredo; Brennan, Cameron; Zacharia, Brad E; Silva Correia, Carlos Eduardo; Diwanji, Madhavi; Pennock, Gregory K; Scott, Charles; Perez-Olle, Raul; Andrews, David W; Boockvar, John A.
Afiliação
  • Lee IY; Henry Ford Health System, Detroit, MI 48202, USA.
  • Hanft S; Westchester Medical Center, Valhalla, NY 10595, USA.
  • Schulder M; Northwell Health at North Shore University Hospital, Lake Success, NY 11030, USA.
  • Judy KD; Thomas Jefferson University, Philadelphia, PA 19107, USA.
  • Wong ET; Rhode Island Hospital & The Warren Alpert Medical School of Brown University, Providence, RI 02912, USA.
  • Elder JB; Ohio State University, Columbus, OH 43210, USA.
  • Evans LT; Dartmouth Hitchcock Medical Center, Lebanon, NH 03766, USA.
  • Zuccarello M; University of Cincinnati Medical Center, Cincinnati, OH 45219, USA.
  • Wu J; Tufts Medical Center, Boston, MA 02111, USA.
  • Aulakh S; West Virginia University, Morgantown, WV 26506, USA.
  • Agarwal V; Montefiore Medical Center, Bronx, NY 10467, USA.
  • Ramakrishna R; Cornell University Weill Medical Center, New York, NY 10065, USA.
  • Gill BJ; Columbia University Medical Center, New York, NY 10019, USA.
  • Quiñones-Hinojosa A; Mayo Clinic, Jacksonville, FL 32224, USA.
  • Brennan C; Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Zacharia BE; Penn State University, Hershey, PA 17036, USA.
  • Silva Correia CE; Jersey Shore University Medical Center, Neptune City, NJ 07753, USA.
  • Diwanji M; Imvax, Inc., Philadelphia, PA 19106, USA.
  • Pennock GK; Imvax, Inc., Philadelphia, PA 19106, USA.
  • Scott C; Imvax, Inc., Philadelphia, PA 19106, USA.
  • Perez-Olle R; Imvax, Inc., Philadelphia, PA 19106, USA.
  • Andrews DW; Imvax, Inc., Philadelphia, PA 19106, USA.
  • Boockvar JA; Lenox Hill Hospital, New York, NY 10075, USA.
Future Oncol ; 20(10): 579-591, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38060340
Glioblastoma (GBM) is a fast-growing brain tumor that happens in about half of all gliomas. Surgery is the first treatment for patients with newly diagnosed GBM, followed by the usual radiation and chemotherapy pills named temozolomide. Temozolomide pills are then given as a long-term treatment. The outcome for the patient with newly diagnosed GBM remains poor. IGV-001 is specially made for each patient. The tumor cells are removed during surgery and mixed in the laboratory with a small DNA, IMV-001. This mix is the IGV-001 therapy that is designed to give antitumor immunity against GBM. IGV-001 is put into small biodiffusion chambers that are irradiated to stop the growth of any tumor cells in the chambers. In the phase IIb study, patients with newly diagnosed GBM are chosen and assigned to either the IGV-001 or the placebo group. A placebo does not contain any active ingredients. The small biodiffusion chambers containing either IGV-001 or placebo are surgically placed into the belly for 48 to 52 h and then removed. Patients then receive the usual radiation and chemotherapy treatment. Patients must be adults aged between 18 and 70 years. Patients also should be able to care for themselves overall, but may be unable to work or have lower ability to function. Patients with tumors on both sides of the brain are not eligible. The main point of this study is to see if IGV-001 helps patients live longer without making the illness worse compared with placebo. Clinical Trial Registration: NCT04485949 (ClinicalTrials.gov).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Combinação de Medicamentos Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioblastoma / Combinação de Medicamentos Limite: Humans Idioma: En Revista: Future Oncol Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos